CLDXCelldex Therapeutics, Inc.同业对比
Celldex Therapeutics, Inc. 与SIC 2835 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLDX本股 | $2.3B#4 | — | 3.3x#9 | 1510.6x#14 | -78.0%#14 | -63.9%#14 | -18599.8%#12 | -36.2%#5 | — | — | 20.1%#4 | — |
| IDXX | $53.0B#1 | 45.3x#3 | 28.3x#12 | 12.3x#10 | 10.4%#4 | 19.3%#9 | 31.6%#1 | 56.7%#1 | 53.2%#1 | 9#1 | -7.0%#5 | — |
| LNTH | $6.6B#2 | 24.1x#2 | 5.0x#10 | 4.3x#8 | 0.5%#6 | -25.2%#12 | 20.2%#2 | 17.8%#2 | 18.1%#2 | 4#4 | — | 0.0%#1 |
| NEOG | $2.6B#3 | — | 1.3x#5 | 3.0x#7 | -2.7%#9 | 99.3%#1 | -2.5%#3 | -0.4%#3 | -0.8%#3 | 5#2 | 92.2%#1 | — |
| NTLA | $1.7B#5 | — | 2.3x#8 | 24.6x#12 | 16.9%#3 | 20.5%#8 | -651.7%#9 | -56.7%#6 | — | — | -9.3%#6 | — |
| QDEL | $969M#6 | — | 0.5x#3 | 0.4x#1 | -1.9%#8 | 44.8%#3 | -33.7%#4 | -63.2%#7 | -19.4%#4 | — | — | — |
| ACHV | $695M#7 | — | — | — | — | -37.2%#13 | — | — | — | — | 32.2%#3 | — |
| MYGN | $578M#8 | — | 1.9x#6 | 0.7x#2 | -1.6%#7 | -188.2%#15 | -47.0%#6 | -120.4%#12 | -76.1%#7 | — | — | — |
| TKNO | $394M#9 | — | 6.3x#11 | 9.7x#9 | 7.4%#5 | 35.5%#4 | -41.9%#5 | -27.6%#4 | -25.2%#5 | 5#2 | 44.4%#2 | — |
| ICCC | $96M#10 | — | — | — | — | — | — | — | — | — | — | — |
| IMDX | $90M#11 | — | — | 22.1x#11 | 115.6%#1 | 17.2%#10 | -1260.8%#11 | — | — | — | — | — |
| BMRA | $8M#12 | — | 2.2x#7 | 1.8x#4 | -16.2%#11 | 24.1%#5 | -119.5%#7 | -103.5%#11 | — | — | — | — |
| CDIO | $5M#13 | — | 0.6x#4 | 321.4x#13 | -57.5%#12 | 22.5%#6 | -43737.5%#13 | -87.5%#9 | — | — | — | — |
| QCLS | $3M#14 | 0.0x#1 | 0.2x#2 | 2.2x#5 | -5.3%#10 | 50.2%#2 | -624.4%#8 | -72.3%#8 | -61.2%#6 | — | — | — |
| VNRX | $3M#15 | — | — | 1.5x#3 | 40.0%#2 | 13.4%#11 | -1258.5%#10 | — | — | — | — | — |
| CDIOW | $40249#16 | — | 0.0x#1 | 2.7x#6 | -57.5%#12 | 22.5%#6 | -43737.5%#13 | -87.5%#9 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议